Pharmaceuticals

Norgine welcomes PBS listing in Australia of IFINWIL? (eflornithine) for patients with high-risk neuroblastoma (HRNB)

 This news is for Australian Media only * Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC)?recommended the listing of eflornithine?for post-maintenance treatment to prevent relapse in p...

2025-08-01 06:01 1701

Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Received U.S. FDA IND Approval to Initiate a Phase II Clinical Study for Platinum-Resistant Ovarian Cancer

 SUZHOU, China, July 31, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic?antibody-drug conjugate (ADC) JSKN003 has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical study inthe United States (study n...

2025-07-31 18:36 2244

Emerald Clinical Trials Confirms CEO Transition and Continuity Plan

 SINGAPORE, July 30, 2025 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization, today announced a leadership transition. Mary?Gunn has stepped down effective immediately.?The Board has appointedGlenn Kerkhof, a long-standing Board member and experienced CRO exec...

2025-07-30 20:00 1899

Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company

 - First global out-licensing deal since founding — tangible return on new drug development investments - Significant milestone payments and future revenue expected — additional out-licensing of proprietary technologies anticipated SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- Dx&Vx (DXVX) ha...

2025-07-30 20:00 2151

Telix H1 2025 Results: Investor Webcast Notification

 MELBOURNE, Australia?and INDIANAPOLIS, July 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended30 June 2025 on Thursday21 August 2025. An investor webcast and conference call wi...

2025-07-30 07:00 2547

Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress

 PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe?atopic dermatitis (AD), wi...

2025-07-29 20:00 1694

Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ

 SUZHOU, China, July 29, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer?and ga...

2025-07-29 10:37 1716

Antengene Announces XPOVIO? Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

 - This approval for XPOVIO? in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug inChina. - XPOVIO? as a monotherapy in patients with relap...

2025-07-28 18:49 2061

Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis

 KOLKATA, India, July 28, 2025 /PRNewswire/ -- In a landmark achievement, a 60-year-old woman with advanced primary peritoneal carcinomatosis was successfully treated withCytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)at Manipal Hospital Dhakuria, under ...

2025-07-28 15:20 1443

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025

 SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for canc...

2025-07-28 10:40 1600

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore

 Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials inSingapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therap...

2025-07-28 07:33 1515

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

 SUZHOU, China, July 26, 2025 /PRNewswire/ --?The?Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line re...

2025-07-26 07:30 3755

Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program

 SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that FDA has design...

2025-07-25 22:59 3570

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

 SHANGHAI, July 25, 2025 /PRNewswire/ --?Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and...

2025-07-25 10:30 2592

Colorcon Celebrates Grand Opening of New Manufacturing Facility in Malaysia

 Johor plant is Colorcon's 7th major film coating plant and 16th manufacturing facility worldwide HARLEYSVILLE, Pa. and JOHOR, Malaysia, July 24, 2025 /PRNewswire/ -- Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere...

2025-07-24 22:00 2730

AMSC Malaysia 2025 Set to Spotlight World-Class Expertise and Innovation in Aesthetic Medicine and Surgery

KUALA LUMPUR, Malaysia, July 24, 2025 /PRNewswire/ --?The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) ?returns for its fourth edition fromAugust 6-7, 2025, with an expanded focus on global participation and advanced education. Held at theKuala Lumpur Conv...

2025-07-24 20:24 3676

Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025

 * Fully Unmanned—?CURECA?, the 100% Automated Diagnostic System Defining the Future Gold Standard, Debuts inChicago, July 28–31 * Unifying global diagnostic data -?STAgora?, the big data platform set to transform the future of diagnostics * Offering early access to the new diagnostic parad...

2025-07-24 17:36 1815

Telix Reports $204M Revenue, Up 63% YOY

 MELBOURNE, Australia?and INDIANAPOLIS, July 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended30 June 2025 (Q2 2025).?All figures are in USD unless stated otherwise. ...

2025-07-22 16:02 2221

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

 SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving inAsia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new expert-driven report finds. Released today, 'On the Cusp o...

2025-07-22 10:07 2531

CPHI & PMEC Shenzhen 2025: Unlocking New Opportunities in Asia and the Greater Bay Area

SHANGHAI, July 21, 2025 /PRNewswire/ -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, underscoring strong demand within China's thriving pharma industry.? Building on this success, CPHI &?PMEC Shenzhen 2025 ?will tak...

2025-07-21 14:31 1808